{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:09:00Z","timestamp":1765609740179,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T00:00:00Z","timestamp":1479945600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s00228-016-2158-2","type":"journal-article","created":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T01:01:55Z","timestamp":1479949315000},"page":"233-239","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-world risk of diabetes with antipsychotic use in older New Zealanders: a case-crossover study"],"prefix":"10.1007","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4155-8540","authenticated-orcid":false,"given":"Prasad S.","family":"Nishtala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Te-yuan","family":"Chyou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,24]]},"reference":[{"issue":"Suppl 10","key":"2158_CR1","first-page":"31","volume":"60","author":"SM Stahl","year":"1999","unstructured":"Stahl SM (1999) Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. The Journal of clinical psychiatry 60(Suppl 10):31\u201341","journal-title":"The Journal of clinical psychiatry"},{"issue":"4","key":"2158_CR2","first-page":"446","volume":"21","author":"M Jakovljevic","year":"2009","unstructured":"Jakovljevic M (2009) New generation vs. first generation antipsychotics debate: pragmatic clinical trials and practice-based evidence. Psychiatr Danub 21(4):446\u2013452","journal-title":"Psychiatr Danub"},{"issue":"2","key":"2158_CR3","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/JCP.0b013e3182114d21","volume":"31","author":"M Lambert","year":"2011","unstructured":"Lambert M, Schimmelmann BG, Schacht A, Suarez D, Haro JM, Novick D, Wagner T, Wehmeier PM, Huber CG, Hundemer HP, Dittmann RW, Naber D (2011) Differential 3-year effects of first- versus second-generation antipsychotics on subjective well-being in schizophrenia using marginal structural models. J Clin Psychopharmacol 31(2):226\u2013230. doi: 10.1097\/JCP.0b013e3182114d21","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"2158_CR4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0895-4356(02)00588-7","volume":"56","author":"JB Buse","year":"2003","unstructured":"Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L (2003) A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 56(2):164\u2013170","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"2158_CR5","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.4088\/JCP.v63n1208","volume":"63","author":"JJ Caro","year":"2002","unstructured":"Caro JJ, Ward A, Levinton C, Robinson K (2002) The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. The Journal of clinical psychiatry 63(12):1135\u20131139","journal-title":"The Journal of clinical psychiatry"},{"issue":"1","key":"2158_CR6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1525-8610(04)70042-0","volume":"5","author":"PD Feldman","year":"2004","unstructured":"Feldman PD, Hay LK, Deberdt W, Kennedy JS, Hutchins DS, Hay DP, Hardy TA, Hoffmann VP, Hornbuckle K, Breier A (2004) Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States. J Am Med Dir Assoc 5(1):38\u201346","journal-title":"J Am Med Dir Assoc"},{"issue":"8","key":"2158_CR7","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1592\/phco.23.8.1037.32876","volume":"23","author":"MA Fuller","year":"2003","unstructured":"Fuller MA, Shermock KM, Secic M, Grogg AL (2003) Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 23(8):1037\u20131043","journal-title":"Pharmacotherapy"},{"key":"2158_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/1471-244x-11-197","volume":"11","author":"M Ulcickas Yood","year":"2011","unstructured":"Ulcickas Yood M, Delorenze GN, Quesenberry CP Jr, Oliveria SA, Tsai AL, Kim E, Cziraky MJ, McQuade RD, Newcomer JW, L'Italien GJ (2011) Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose? BMC psychiatry 11:197. doi: 10.1186\/1471-244x-11-197","journal-title":"BMC psychiatry"},{"issue":"9","key":"2158_CR9","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/pds.1781","volume":"18","author":"MU Yood","year":"2009","unstructured":"Yood MU, DeLorenze G, Quesenberry CP Jr, Oliveria SA, Tsai AL, Willey VJ, McQuade R, Newcomer J, L\u2019Italien G (2009) The incidence of diabetes in atypical antipsychotic users differs according to agent\u2014results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 18(9):791\u2013799. doi: 10.1002\/pds.1781","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"2158_CR10","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.cct.2004.09.002","volume":"25","author":"JH Montgomery","year":"2004","unstructured":"Montgomery JH, Byerly M, Carmody T, Li B, Miller DR, Varghese F, Holland R (2004) An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Control Clin Trials 25(6):598\u2013612. doi: 10.1016\/j.cct.2004.09.002","journal-title":"Control Clin Trials"},{"issue":"5","key":"2158_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1192\/bjp.bp.111.101485","volume":"200","author":"MJ Peluso","year":"2012","unstructured":"Peluso MJ, Lewis SW, Barnes TR, Jones PB (2012) Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. The British journal of psychiatry : the journal of mental science 200(5):387\u2013392. doi: 10.1192\/bjp.bp.111.101485","journal-title":"The British journal of psychiatry : the journal of mental science"},{"issue":"1","key":"2158_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/0962280208092346","volume":"18","author":"JA Delaney","year":"2009","unstructured":"Delaney JA, Suissa S (2009) The case-crossover study design in pharmacoepidemiology. Stat Methods Med Res 18(1):53\u201365. doi: 10.1177\/0962280208092346","journal-title":"Stat Methods Med Res"},{"issue":"2","key":"2158_CR13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/oxfordjournals.aje.a115853","volume":"133","author":"M Maclure","year":"1991","unstructured":"Maclure M (1991) The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 133(2):144\u2013153","journal-title":"Am J Epidemiol"},{"issue":"7","key":"2158_CR14","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/pds.2140","volume":"20","author":"CH Chang","year":"2011","unstructured":"Chang CH, Chen HC, Lin JW, Kuo CW, Shau WY, Lai MS (2011) Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan. Pharmacoepidemiol Drug Saf 20(7):763\u2013771. doi: 10.1002\/pds.2140","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"2158_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/jcp.0000000000000465","volume":"36","author":"PF Schulte","year":"2016","unstructured":"Schulte PF, Bocxe JT, Doodeman HJ, van Haelst IM, Cohen D (2016) Risk of new-onset diabetes after long-term treatment with clozapine in comparison to other antipsychotics in patients with schizophrenia. J Clin Psychopharmacol 36(2):115\u2013119. doi: 10.1097\/jcp.0000000000000465","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"2158_CR16","doi-asserted-by":"publisher","first-page":"e150285","DOI":"10.1001\/jamapediatrics.2015.0285","volume":"169","author":"DM Rubin","year":"2015","unstructured":"Rubin DM, Kreider AR, Matone M, Huang YS, Feudtner C, Ross ME, Localio AR (2015) Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths. JAMA Pediatr 169(4):e150285. doi: 10.1001\/jamapediatrics.2015.0285","journal-title":"JAMA Pediatr"},{"issue":"4","key":"2158_CR17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1023\/A:1020464017021","volume":"73","author":"R Tandon","year":"2002","unstructured":"Tandon R (2002) Safety and tolerability: how do newer generation \u201catypical\u201d antipsychotics compare? The Psychiatric quarterly 73(4):297\u2013311","journal-title":"The Psychiatric quarterly"},{"issue":"1","key":"2158_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.12865\/chsj.40.01.02","volume":"40","author":"IC Miron","year":"2014","unstructured":"Miron IC, Baroana VC, Popescu F, Ionica F (2014) Pharmacological mechanisms underlying the association of antipsychotics with metabolic disorders. Current health sciences journal 40(1):12\u201317. doi: 10.12865\/chsj.40.01.02","journal-title":"Current health sciences journal"},{"issue":"9","key":"2158_CR19","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1038\/npp.2010.78","volume":"35","author":"J Nielsen","year":"2010","unstructured":"Nielsen J, Skadhede S, Correll CU (2010) Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 35(9):1997\u20132004. doi: 10.1038\/npp.2010.78","journal-title":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology"},{"key":"2158_CR20","doi-asserted-by":"crossref","unstructured":"2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27(2):596\u2013601","DOI":"10.2337\/diacare.27.2.596"},{"issue":"1","key":"2158_CR21","first-page":"11","volume":"42","author":"RA Baker","year":"2009","unstructured":"Baker RA, Pikalov A, Tran QV, Kremenets T, Arani RB, Doraiswamy PM (2009) Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration adverse event database: a systematic Bayesian signal detection analysis. Psychopharmacol Bull 42(1):11\u201331","journal-title":"Psychopharmacol Bull"},{"issue":"1","key":"2158_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/10401230701844612","volume":"20","author":"W DuMouchel","year":"2008","unstructured":"DuMouchel W, Fram D, Yang X, Mahmoud RA, Grogg AL, Engelhart L, Ramaswamy K (2008) Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004). Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 20(1):21\u201331. doi: 10.1080\/10401230701844612","journal-title":"Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists"},{"issue":"1","key":"2158_CR23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00001648-200201000-00016","volume":"13","author":"W Navidi","year":"2002","unstructured":"Navidi W, Weinhandl E (2002) Risk set sampling for case-crossover designs. Epidemiology 13(1):100\u2013105","journal-title":"Epidemiology"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2158-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-016-2158-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2158-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T00:22:15Z","timestamp":1498350135000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-016-2158-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,24]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["2158"],"URL":"https:\/\/doi.org\/10.1007\/s00228-016-2158-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2016,11,24]]}}}